Balderton and Sofinnova inject €4.5m into MyTomorrows

The funding will enable the company to invest in the development of decision-making tools for its platform and establish business operations in the US. It will also allow MyTomorrows to increase the number of diseases it focuses on.

The investment represents the business's first round of institutional financing.

The new backers stated they were attracted to the company by the potential social impact of its product and by its ability to safely capitalise on recent government legislation designed to increase access to early-stage drugs.

Company
Headquartered in Amsterdam and founded in 2013, MyTomorrows is an online healthcare platform for people suffering from debilitating diseases. The company currently specialises in medical needs across oncology, central nervous system and orphan diseases.

MyTomorrows makes use of programmes known as "compassionate use programmes" to allow patients access to experimental drugs. The online platform aims to simplify the existing process, which the company describes as "highly complex and bureaucratic".

People
Mark Evans is a general partner at Balderton. Antoine Papiernik is managing partner at Sofinnova. Erdem Yavuz and Ronald Brus are co-founders and CEOs of MyTomorrows.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Benelux
• Netherlands
• Sofinnova Partners
• Balderton Capital